TY
Zoetis Pipeline
| Drug | Indication | Phase |
|---|---|---|
| APOQUEL (oclacitinib) | Canine atopic dermatitis | Commercial |
| CYTOPOINT (lokivetmab) | Canine atopic dermatitis | Commercial |
| Revolution Plus | Feline parasiticides | Commercial |
| Draxxin | Bovine respiratory disease | Commercial |
| Suvaxyn PCV | Porcine circovirus | Commercial |
| Vanguard Plus 5 | Canine core vaccines | Commercial |
| STRONGHOLD Plus | Feline parasiticides | Commercial |
Leadership Team at Zoetis
KP
Kristin Peck
Chief Executive Officer
WJ
Wetteny Joseph
Chief Financial Officer
RL
Roxanne Lagano
Executive Vice President and Chief Digital & Technology Officer
RT
Roman Trawicki
Group President, International
HC
Heidi Chen
Executive Vice President, Chief Legal Officer and Corporate Secretary
GD
Glenn David
Executive Vice President, Chief Human Resources Officer